Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Sep;10(Suppl 26):S3071-S3077.
doi: 10.21037/jtd.2018.07.52.

Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial

Kentaro Ito  1 , Osamu Hataji  1
Affiliations
Editorial

Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial

Kentaro Ito et al. J Thorac Dis. 2018 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Honoraria: Boehringer Ingelheim, AstraZeneca, Chugai Pharmaceutical Co, MSD, Ono Pharmaceutical Co, Eli Lilly, Shionogi Pharmaceutical Co; Research funding: GlaxoSmithKlein, Novartis, Daiichi-Sankyo, Boehringer Ingelheim, AstraZeneca, Chugai Pharmaceutical Co, Ono Pharmaceutical Co, Kyorin Pharmaceutical Co.

Comment on

References

    1. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8. 10.1056/NEJMoa0909530 - DOI - PubMed
    1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. 10.1056/NEJMoa0810699 - DOI - PubMed
    1. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46. 10.1016/S1470-2045(11)70393-X - DOI - PubMed
    1. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34. 10.1200/JCO.2012.44.2806 - DOI - PubMed
    1. Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 2015;26:1883-9. 10.1093/annonc/mdv270 - DOI - PubMed